Combined use of sodium borocaptate and buthionine sulfoximine in boron neutron capture therapy enhanced tissue boron uptake and delayed tumor growth in a rat subcutaneous tumor model

Cancer Lett. 2008 May 18;263(2):253-8. doi: 10.1016/j.canlet.2008.01.016. Epub 2008 Feb 12.

Abstract

We have previously reported that buthionine sulfoximine (BSO) enhances sodium borocaptate (BSH) uptake by down regulating glutathione (GSH) synthesis in cultured cells. This study investigated the influence of BSO on tissue BSH uptake in vivo and the efficacy of BSH-BSO-mediated boron neutron capture therapy (BNCT) on tumor growth using a Fisher-344 rat subcutaneous tumor model. With BSO supplementation, boron uptake in subcutaneous tumor, blood, skin, muscle, liver, and kidney was significantly enhanced and maintained for 12h. Tumor growth was significantly delayed by using BSO. With further improvement in experimental conditions, radiation exposure time, together with radiation damage to normal tissues, could be reduced.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Animals
  • Borohydrides / administration & dosage
  • Borohydrides / pharmacology*
  • Boron / metabolism*
  • Boron Neutron Capture Therapy / methods*
  • Buthionine Sulfoximine / administration & dosage
  • Buthionine Sulfoximine / pharmacology*
  • Isotopes / metabolism
  • Male
  • Neoplasm Transplantation
  • Neoplasms, Experimental / radiotherapy*
  • Rats
  • Rats, Inbred F344
  • Sulfhydryl Compounds / administration & dosage
  • Sulfhydryl Compounds / pharmacology*

Substances

  • Borohydrides
  • Isotopes
  • Sulfhydryl Compounds
  • mercaptoundecahydrododecaborate
  • Buthionine Sulfoximine
  • Boron